Event coverage ASCO 2018 - Monday 4th June: BMS tries different tack as Mer... Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News ASCO to shine light on CAR-T developments Kite, Juno, and BlueBird will give updates on T-cell therapies.
Views & Analysis ASCO 2017: Breast cancer next target for Keytruda Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.
News EU clears AZ's SERD camizestrant, as FDA review drags on AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
